Immunosuppressants - China | Statista Market Forecast

In China, the revenue in the Immunosuppressants market is estimated to reach US$4.09bn in 2024.
It is anticipated that there will be an annual growth rate (CAGR 2024-2029) of 15.82%, leading to a market volume of US$8.53bn by 2029.
When compared globally, United States is expected to generate the highest revenue in the Immunosuppressants market, with US$35.47bn in 2024.
China's growing demand for immunosuppressants is driven by an aging population and increasing prevalence of organ transplantation.

Definition:
The Immunosuppressants market covers drugs which suppress the immune response. These remedies are used in different therapy areas, mainly to treat auto-immune diseases, such as psoriasis. Anti-rejection drugs administered after organ transplantations are also included in this market. Monoclonal antibodies are an important type of immunosuppressant.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Johnson & Johnson, Sanofi, Novartis

Drugs to suppress the immune response
Immunosuppressants to treat auto-immune diseases, such as psoriasis
Anti-rejection drugs

Multiple sclerosis drugs
Anti-rheumatic drugs
Immuno-oncology drugs
Antivirals
Antibiotics
Corticosteroids
HIV drugs

The Immunosuppressants market in China has been experiencing steady growth over the past few years.

Customer preferences: Patients in China suffering from autoimmune diseases such as rheumatoid arthritis and lupus are the primary consumers of immunosuppressants. These patients require long-term medication and are therefore a reliable source of demand for immunosuppressants.

Trends in the market: The market for immunosuppressants in China is being driven by an increase in the prevalence of autoimmune diseases, coupled with an aging population. Additionally, the Chinese government has been increasing its investment in healthcare, which has led to an increase in the availability of immunosuppressants in the country. This has helped to boost demand, as more patients are now able to access the medication they need.

Local special circumstances: One factor that has had a significant impact on the immunosuppressants market in China is the country's healthcare system. The government has been working to reform the healthcare system, with a focus on improving access to healthcare for all citizens. This has led to an increase in the availability of immunosuppressants, as well as other medications, in the country.

Underlying macroeconomic factors: China's growing economy has also played a role in the growth of the immunosuppressants market. As the country's middle class has grown, so too has demand for healthcare services and medication. Additionally, the government's focus on healthcare reform has helped to boost the market, as more patients are now able to access the medication they need. Overall, the future looks bright for the immunosuppressants market in China, as demand is expected to continue to grow in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.